About
One of the major challenges in the fight against cancer is to find and identify the cancer cells. In this disease, it is our own cells that lose control, so cancer cells look like every other cell in our body and it is challenging to differentiate healthy cells from the diseased cancer cells. All cells are covered with a dense protective sugar-coating. Cancer cells shield themselves with sugar-coat masks to look just like healthy cells, but their sugar-coating is actually slightly different.
Glyconia unlocked the code for identifying cancer cells and killing them specifically, based on their unique sugar-coating, that is different from healthy cells.
Glyconia has a unique platform and multidisciplinary know-how, leading the development of breakthrough CAR-T immunotherapy, targeting the sugar-coating on cancer cells. Glyconia has a proprietary technology that allows targeting cancer cell-surface glycosylation at high efficiency and potency.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Glyconia's primary focus in cancer treatment?
- Glyconia focuses on developing breakthrough CAR-T immunotherapy that targets the unique sugar-coating on cancer cells to specifically identify and kill them.
- When was Glyconia founded?
- Glyconia was founded in June 2022.
- What is Glyconia's current operational status?
- Glyconia is currently inactive and ceased to operate in January 2024.
- Where is Glyconia headquartered?
- Glyconia is headquartered in Rosh Haayin, Israel.
- What is Glyconia's current funding stage?
- Glyconia is in the Pre-Funding stage, with a total raised amount of $0 USD.
- How many employees does Glyconia have?
- Glyconia has between 1-10 employees.
- Who is a founder of Glyconia?
- Vered Padler-Karavani is a founder of Glyconia.
- What sector does Glyconia operate in?
- Glyconia operates primarily in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.